Prognosis varies with the type of<unk>  and the affected organ system. Prognosis for untreated<unk>  cardiac<unk>  is poor, with a median survival of six months. More specifically,<unk> <unk>  can be classified as stage I, II or III based on cardiac biomarkers like Nt-proBNP and cardiac troponin. Survival diminishes with increasing stage, however recent advancements in treatments have improved median survival rates for stages I, II, and III, to 91.2, 60, and 7 months respectively. Outcomes in a person with AA<unk>  depend on the underlying disease, organ(s) affected, and correlate with the concentration of serum amyloid A protein. People with ATTR, mutant ATTR and wild-type ATTR have a better prognosis when compared to people with<unk>  and may survive for over a decade. Survival time is not associated with gender or age, however, some measures of reduced heart function are associated with a shorter survival time. Senile systemic<unk>  was determined to be the primary cause of death for 70% of people over 110 who have been autopsied.
Amyloidosis
Sjögren syndrome  Sjögren syndrome  1
Gamasoidosis
Melioidosis
Sarcoidosis
Amyloid cardiomyopathy
Neurosarcoidosis
Cardiac amyloidosis